Last reviewed · How we verify
NCT06764251
Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma
Phase 2 trial testing Tislelizumab + SOX in Gastric/Gastroesophageal Junction Adenocarcinoma in 20 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Liaoning Cancer Hospital & Institute |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 30 December 2024 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 March 2028 |
Drugs / interventions tested
- Tislelizumab + SOX — full drug profile →
Conditions studied
- Gastric/Gastroesophageal Junction Adenocarcinoma — all drugs for Gastric/Gastroesophageal Junction Adenocarcinoma →
Sponsor
Liaoning Cancer Hospital & Institute
Who can join
Adults 18 to 70, any sex, with Gastric/Gastroesophageal Junction Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06764251
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric/Gastroesophageal Junction Adenocarcinoma
Currently open trials in the same condition.
- NCT06415669 — A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma · Phase 2 · recruiting
- NCT06774222 — A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG · Phase 2 · recruiting
- NCT04895709 — A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid · Phase 1, PHASE2 · recruiting
Other Liaoning Cancer Hospital & Institute trials
Trials by the same sponsor.
- NCT07161453 — Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinom · Phase 4 · not yet recruiting
- NCT07132528 — Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After · Phase 4 · not yet recruiting
- NCT07149181 — Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regim · Phase 4 · not yet recruiting
- NCT06908733 — Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC · Phase 2 · not yet recruiting
- NCT06299371 — Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06764251 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liaoning Cancer Hospital & Institute
- Last refreshed: 8 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06764251.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing